Hims, Super Bowl and Hers
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, which both contain the active ingredient semaglutide and are approved by the U.S. Food and Drug Administration to treat Type 2 diabetes and obesity, respectively.
The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.
Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
Hims & Hers, a San Francisco-headquartered telehealth company, ran its controversial Super Bowl commercial despite multiple ...
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
Hims & Hers' “Sick of the System” spot not only generated the highest engagement of all pharma-related ads that aired during ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback